·糖尿病胰岛素治疗·

　　【摘要】 目的 比较门诊胰岛素泵、住院胰岛素泵及门诊多次皮下注射胰岛素治疗T2DM的疗效。 方法 收集门诊胰岛素泵、住院胰岛素泵及门诊多次皮下注射胰岛素的患者，观察血糖控制情况、达标时间、胰岛素用量、低血糖发生率、治疗费用。结果 门诊胰岛素泵组与住院胰岛素泵组相比，血糖达标时间、胰岛素用量、低血糖发生率等方面比较差异无统计学意义(P>0.05)，但治疗费用明显小于住院胰岛素泵组(P<0.01);门诊胰岛素泵组与4次/d胰岛素注射组相比，在血糖控制情况、达标时间、低血糖发生率等方面比较差异有统计学意义(P<0.01)。结论 门诊胰岛素泵短期强化治疗能平稳有效控制血糖，且费用低于住院胰岛素泵，降糖效果优于门诊四针注射。

　　【关键词】 门诊;胰岛素泵;强化治疗;糖尿病, 2型

Clinical study on the T2DM patients treated with insulin pump short-term intensive treatment SUI Miao, CHEN Jun, DING Kai, et al. Department of Endocrinology, Xuzhou Municipal Hospital of Chinese Medicine, Jiangsu Province, Xuzhou 221000, China

　　【Abstract】Objective To compare the effect of treatment for T2DM with outpatient insulin pump, inpatient insulin pump, and outpatient multiple daily injection. Methods The T2DM patients treated with outpatient insulin pump, inpatient insulin pump and outpatient multiple daily injection were collected for the observation. The condition of these patients, including the glycemic control, the time to achieve the glycemic control, insulin dosage, incidence of hypoglycemia, treatment costs, was studied for comparison. Results There was no statistical difference in the time to achieve the glycemic control, insulin dosage, and incidence of hypoglycemia between the outpatient insulin pump group and the inpatient insulin pump group (P>0.05), while the cost of treatment of the outpatient insulin pump group was significantly less than that of the inpatient insulin pump group (P<0.01). There was a statistical difference in the glycemic control, the time to the achieve glycemic control, and incidence of hypoglycemia between the outpatient insulin pump group and the outpatient 4 times daily injection group (P<0.01). Conclusion The outpatient insulin pump short-term intensive treatment can smoothly and effectively control the blood glucose, the cost is lower than that of the inpatient insulin pump treatment, and the glucose-lowering effect is better than that of 4 times daily injection.

　　【Key words】Outpatient; Insulin pump; Continuous subcutaneous insulin infusion (CSII); Intensive treatment; Diabetes mellitus, type 2